European Union’s ‘Digital Market Act’ Is Good, but for Online Users - It’s Not Good Enough
28.3.2022 14:00:00 EEST | Business Wire | Press release
Several international digital specialists have praised the EU’s Digital Market Act, but say its primary aim is to foster competition among tech companies while trying to reign in some of the tech giants. They say its primary focus is not protecting the personal information of digital users.
“The Digital Market Act definitely places some constraints on how some of these tech giants can use consumers’ personal data, but in terms of giving them control over their own personal information, it comes up short,” said Dr Paul Twomey, one of the lead authors of a report entitled Empowering Digital Citizens.
The report, culminating two-years of work, was presented at the Global Solutions Summit in Berlin, Germany on 28 March 2022. The annual conference brings together senior government officials with top-level academic researchers, NGO leaders, and international CEOs. It transforms research-based insights into policy recommendations for the Group of Seven (G7) and Group of 20 (G20) inter-governmental forums.
“The buying and selling of personal data is part of a $515 billion (USD) market,” says Professor Dennis J. Snower, the report’s other lead author. “Digital users are simply not a part of this transactional system and in many cases don’t even know that it exists, nor do they know who has their personal information or how it is being used. We want humane market dynamics to apply to all participants in the online economy.”
Under the Empowering Digital Citizens proposal, online users would be given control over who has access to the personally identifiable information they create. They can also, with the help of a representative, set the terms under which their data can be used (according to the law), and in return they need to ensure that their data is accurate and verified by trusted third parties. “Only the illicit drug market and online data aggregators refer to people as users,“ says Twomey. “These proposals transform that model. They empower a world of digital citizens able to reinforce their democratic rights and counter the forces of disinformation.”
Twomey and Snower represent the Global Initiative for Digital Empowerment (GIDE), which is made up of over 70 specialists from around the world, including policy experts, researchers, Internet technical experts, business people, security specialists and others. GIDE is an initiative of THE NEW INSTITUTE. Based in Hamburg, THE NEW INSTITUTE is an institute of advanced studies and a platform to find answers to the most pressing ecological, economic and political challenges of our time.
The two digital researchers say a major problem is that many online users of “free services” are given artificially restricted choices of either revealing large amounts of personal data (by agreeing to the terms and conditions of digital services) or being excluded from the economic and social interactions that define modern life.
The Empowering Digital Citizens initiative will make online and digital consumers part of the economic model that is currently invisible to the average consumer.
Access the report here: Empowering Digital Citizens. Access an FAQ on the initiative here: Q&A on Human-Centered Digital Governance.
Membership of the Global Initiative for Digital Empowerment is on page four of the Empowering Digital Citizens report.
About Dr. Paul Twomey: Dr. Twomey is co-lead of the Global Initiative for Digital Empowerment and Fellow and Initiative Director for Digital Governance at THE NEW INSTITUTE. He is a Fellow and Core Theme Leader for “managing information and technology in the public interest” at the Global Solutions Initiative. Twomey is also a Distinguished Fellow at the Centre for International Governance Innovation and a Commissioner of the Global Commission for Internet Governance. He is the former CEO of ICANN, the global coordination body of the Internet’s addressing system.
About Prof. Dennis J. Snower: Prof. Snower is co-lead of the Global Initiative for Digital Empowerment and is the director for the Socio-Economic Transformation programme at THE NEW INSTITUTE.. He is founder and President of the Global Solutions Initiative; Professor of Macroeconomics and Sustainability at the Hertie School, Berlin; Senior Research Fellow at the Blavatnik School of Government, Oxford; and Non-resident Fellow of Brookings Institution. He is co-lead of this project. He is Research Fellow at the Centre for Economic Policy Research (London), at IZA (Institute for the Future of Work, Bonn), and CESifo (Munich).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005498/en/
Contact information
Georg Diez
The New Institute
Hamburg
Tel: +49 40 3008 2714
press@thenew.institute
Brad White
White Paper Communications LLC
San Diego, CA USA
bradwhite@whitepaper.tv
Tel. +1.301.365.3571
Telegram: @Brad_White_SD
WhatsApp: +1.301.365.3571
Signal: +1.301.365.3571
Skype – bradrwhite
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
